These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34327874)

  • 1. Inflammatory breast cancer appearance at presentation is associated with overall survival.
    Balema W; Liu D; Shen Y; El-Zein R; Debeb BG; Kai M; Overmoyer B; Miller KD; Le-Petross HT; Ueno NT; Woodward WA
    Cancer Med; 2021 Sep; 10(18):6261-6272. PubMed ID: 34327874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial response to chemotherapy, not delay in diagnosis, predicts overall survival in inflammatory breast cancer cases.
    Hoffman HJ; Khan A; Ajmera KM; Zolfaghari L; Schenfeld JR; Levine PH
    Am J Clin Oncol; 2014 Aug; 37(4):315-21. PubMed ID: 23241503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of CNS metastases and survival in patients with inflammatory breast cancer.
    Uemura MI; French JT; Hess KR; Liu D; Raghav K; Hortobagyi GN; Arun BK; Valero V; Ueno NT; Alvarez RH; Woodward WA; Debeb BG; Moulder SL; Lim B; Tripathy D; Ibrahim NK
    Cancer; 2018 Jun; 124(11):2299-2305. PubMed ID: 29579338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression.
    Van Berckelaer C; Rypens C; van Dam P; Pouillon L; Parizel M; Schats KA; Kockx M; Tjalma WAA; Vermeulen P; van Laere S; Bertucci F; Colpaert C; Dirix L
    Breast Cancer Res; 2019 Feb; 21(1):28. PubMed ID: 30777104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rates of Pathologic Complete Response and Overall Survival in Patients with Inflammatory Breast Cancer: A National Cancer Database Study.
    Parrish KM; Thomas SM; Cartwright SB; van den Bruele AB; Zasloff R; DiLalla GA; DiNome ML; Menendez CS; Rosenberger LH; Woriax HE; Hwang ES; Plichta JK; Chiba A
    Ann Surg Oncol; 2024 Nov; 31(12):8057-8067. PubMed ID: 39158638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
    Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
    Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis.
    Jiao D; Zhang J; Zhu J; Guo X; Yang Y; Xiao H; Liu Z
    BMC Cancer; 2021 Feb; 21(1):138. PubMed ID: 33549037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why diagnosing inflammatory breast cancer is hard and how to overcome the challenges: a narrative review.
    Le-Petross HT; Balema W; Woodward WA
    Chin Clin Oncol; 2021 Dec; 10(6):58. PubMed ID: 35016512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor cells in newly diagnosed inflammatory breast cancer.
    Mego M; Giordano A; De Giorgi U; Masuda H; Hsu L; Giuliano M; Fouad TM; Dawood S; Ueno NT; Valero V; Andreopoulou E; Alvarez RH; Woodward WA; Hortobagyi GN; Cristofanilli M; Reuben JM
    Breast Cancer Res; 2015 Jan; 17(1):2. PubMed ID: 25572591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation.
    Lacerda L; Reddy JP; Liu D; Larson R; Li L; Masuda H; Brewer T; Debeb BG; Xu W; Hortobágyi GN; Buchholz TA; Ueno NT; Woodward WA
    Stem Cells Transl Med; 2014 Jul; 3(7):849-56. PubMed ID: 24833589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
    Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marital status is an independent prognostic factor in inflammatory breast cancer patients: an analysis of the surveillance, epidemiology, and end results database.
    Liu YL; Wang DW; Yang ZC; Ma R; Li Z; Suo W; Zhao Z; Li ZW
    Breast Cancer Res Treat; 2019 Nov; 178(2):379-388. PubMed ID: 31414242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes.
    Hieken TJ; Murphy BL; Boughey JC; Degnim AC; Glazebrook KN; Hoskin TL
    Clin Breast Cancer; 2018 Aug; 18(4):e501-e506. PubMed ID: 29089281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-daily radiation therapy for inflammatory breast cancer.
    Brown L; Harmsen W; Blanchard M; Goetz M; Jakub J; Mutter R; Petersen I; Rooney J; Stauder M; Yan E; Laack N
    Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):997-1003. PubMed ID: 24721591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.
    Fouad TM; Kogawa T; Liu DD; Shen Y; Masuda H; El-Zein R; Woodward WA; Chavez-MacGregor M; Alvarez RH; Arun B; Lucci A; Krishnamurthy S; Babiera G; Buchholz TA; Valero V; Ueno NT
    Breast Cancer Res Treat; 2015 Jul; 152(2):407-16. PubMed ID: 26017070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and outcome of bone-only metastasis in inflammatory and noninflammatory breast cancers.
    Kai M; Kogawa T; Liu DD; Fouad TM; Kai K; Niikura N; Hsu L; Willey JS; Theriault RL; Valero V; Ueno NT
    Clin Breast Cancer; 2015 Feb; 15(1):37-42. PubMed ID: 25258308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer.
    Nakhlis F; Regan MM; Warren LE; Bellon JR; Hirshfield-Bartek J; Duggan MM; Dominici LS; Golshan M; Jacene HA; Yeh ED; Mullaney EE; Overmoyer B
    Ann Surg Oncol; 2017 Sep; 24(9):2563-2569. PubMed ID: 28560598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying factors that impact survival among women with inflammatory breast cancer.
    Dawood S; Ueno NT; Valero V; Woodward WA; Buchholz TA; Hortobagyi GN; Gonzalez-Angulo AM; Cristofanilli M
    Ann Oncol; 2012 Apr; 23(4):870-5. PubMed ID: 21765048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with improved outcomes for metastatic inflammatory breast cancer patients.
    Weiss A; Menen RS; Lin HY; Shen Y; Rosso KJ; Shaitelman S; Woodward W; Valero V; Ueno NT; Bedrosian I; Babiera G
    Breast Cancer Res Treat; 2018 Jun; 169(3):615-623. PubMed ID: 29460033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy.
    Tsai CJ; Li J; Gonzalez-Angulo AM; Allen PK; Woodward WA; Ueno NT; Lucci A; Krishnamurthy S; Gong Y; Yang W; Cristofanilli M; Valero V; Buchholz TA
    Am J Clin Oncol; 2015 Jun; 38(3):242-7. PubMed ID: 23648437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.